Loading…
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $129M | $16M | $17M | $13M | 22.7% | 29.9% | 103.3% |
| 2024 | $100M | $9M | $9M | $12M | 18.5% | 19.2% | -273.1% |
| 2023 | $84M | $-4M | $-5M | $7M | -17.4% | 16.0% | -70.1% |
| 2022 | $72M | $-17M | $-17M | $-15M | -57.7% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 72.05 | 83.57 | 99.60 | 129.42 |
| Operating Revenue | - | 72.05 | 83.57 | 99.60 | 129.42 |
| Cost Of Revenue | - | 29.25 | 32.79 | 38.01 | 46.23 |
| Gross Profit | - | 42.80 | 50.78 | 61.59 | 83.19 |
| Operating Expense | - | 61.42 | 56.38 | 53.86 | 68.89 |
| Research And Development | - | 4.83 | 4.96 | 6.02 | 6.33 |
| Selling General And Administration | - | 56.60 | 51.42 | 47.84 | 62.56 |
| Total Expenses | - | 90.68 | 89.17 | 91.87 | 115.13 |
| Operating Income | - | -18.63 | -5.60 | 7.73 | 14.30 |
| Total Operating Income As Reported | - | -18.63 | -5.60 | 7.73 | 16.28 |
| EBITDA | - | -16.74 | -3.89 | 9.21 | 15.75 |
| Normalized EBITDA | - | -16.74 | -3.89 | 9.21 | 13.76 |
| EBIT | - | -18.63 | -5.60 | 7.73 | 14.30 |
| Interest Income | - | 0 | 0.66 | 1.13 | 2.13 |
| Net Interest Income | - | 0 | 0.66 | 1.13 | 2.13 |
| Other Non Operating Income Expenses | - | 2.08 | - | - | -0.21 |
| Other Income Expense | - | 2.08 | - | - | 1.77 |
| Interest Income Non Operating | - | 0 | 0.66 | 1.13 | 2.13 |
| Net Non Operating Interest Income Expense | - | 0 | 0.66 | 1.13 | 2.13 |
| Pretax Income | - | -16.54 | -4.94 | 8.86 | 18.19 |
| Tax Provision | - | - | 0 | 0.30 | 0.81 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0.09 |
| Net Income Continuous Operations | - | -16.54 | -4.94 | 8.55 | 17.38 |
| Net Income From Continuing And Discontinued Operation | - | -16.54 | -4.94 | 8.55 | 17.38 |
| Net Income From Continuing Operation Net Minority Interest | - | -16.54 | -4.94 | 8.55 | 17.38 |
| Net Income | - | -16.54 | -4.94 | 8.55 | 17.38 |
| Net Income Common Stockholders | - | -16.54 | -4.94 | 8.55 | 17.38 |
| Net Income Including Noncontrolling Interests | - | -16.54 | -4.94 | 8.55 | 17.38 |
| Normalized Income | - | -16.54 | -4.94 | 8.55 | 15.49 |
| Diluted NI Availto Com Stockholders | - | -16.54 | -4.94 | 8.55 | 17.38 |
| Basic Average Shares | - | 69.73 | 74.98 | 75.93 | 79.18 |
| Diluted Average Shares | - | 69.73 | 74.98 | 78.12 | 85.44 |
| Reconciled Depreciation | - | 1.88 | 1.70 | 1.48 | 1.45 |
| Reconciled Cost Of Revenue | - | 29.25 | 32.79 | 38.01 | 46.23 |
| Total Unusual Items | - | - | - | 0 | 1.98 |
| Total Unusual Items Excluding Goodwill | - | - | - | 0 | 1.98 |
| Special Income Charges | - | - | - | 0 | 1.98 |
| Other Special Charges | - | - | - | - | -1.98 |
| General And Administrative Expense | - | 28.29 | 24.98 | 18.38 | 27.06 |
| Other Gand A | - | 28.29 | 24.98 | 18.38 | 27.06 |
| Total Other Finance Cost | 0.06 | 0 | - | - | - |
| Selling And Marketing Expense | - | 28.31 | 26.44 | 29.47 | 35.51 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Niagen Bioscience, Inc.this co. | NAGE | $279M | 16.04 | 3.64 | 22.7% | 13.78 |
| Alpha Teknova, Inc. | TKNO | $291M | -16.87 | 4.23 | -25.1% | -30.89 |
| OraSure Technologies, Inc. | OSUR | $287M | -4.18 | 0.84 | -20.2% | -1.74 |
| Quantum-Si incorporated | QSI | $279M | -2.75 | 1.27 | -46.0% | -2.81 |
| Eledon Pharmaceuticals, Inc. | ELDN | $278M |
| - |
| - |
| - |
| - |
| - |
| - |
| -6.09 |
| 3.43 |
| -56.3% |
| -3.08 |
| Entrada Therapeutics, Inc. | TRDA | $272M | -1.89 | 0.89 | -47.0% | -1.51 |
| Anavex Life Sciences Corp. | AVXL | $261M | -5.63 | 2.75 | -48.9% | - |
| Akebia Therapeutics, Inc. | AKBA | $260M | -48.70 | 7.98 | -16.4% | 5.86 |
| Fate Therapeutics, Inc. | FATE | $258M | -1.89 | 1.24 | -65.8% | -2.14 |
| Peer Median | - | -4.91 | 2.01 | -46.5% | -2.14 | |